GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Cyclically Adjusted Price-to-FCF

Diamyd Medical AB (OSTO:DMYD B) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Diamyd Medical AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cyclically Adjusted Price-to-FCF Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diamyd Medical AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Diamyd Medical AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Diamyd Medical AB's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2025 is calculated as:

For example, Diamyd Medical AB's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=-0.47/133.7436*133.7436
=-0.470

Current CPI (Feb. 2025) = 133.7436.

Diamyd Medical AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201505 -0.178 100.285 -0.237
201508 -0.129 99.829 -0.173
201511 -0.168 100.129 -0.224
201602 -0.170 100.253 -0.227
201605 -0.142 100.914 -0.188
201608 -0.118 100.968 -0.156
201611 -0.153 101.517 -0.202
201702 -0.170 102.037 -0.223
201705 -0.179 102.679 -0.233
201708 -0.189 103.138 -0.245
201711 -0.209 103.413 -0.270
201802 -0.189 103.678 -0.244
201805 -0.169 104.632 -0.216
201808 -0.155 105.197 -0.197
201811 -0.186 105.443 -0.236
201902 -0.127 105.641 -0.161
201905 -0.132 106.895 -0.165
201908 -0.799 106.716 -1.001
201911 -0.086 107.345 -0.107
202002 0.523 106.742 0.655
202005 -0.095 106.882 -0.119
202008 -0.101 107.571 -0.126
202011 -0.224 107.549 -0.279
202102 -0.216 108.190 -0.267
202105 -0.377 108.838 -0.463
202108 -0.754 109.780 -0.919
202111 -0.573 111.069 -0.690
202202 -0.278 112.834 -0.330
202205 -0.456 116.746 -0.522
202208 -0.395 120.573 -0.438
202211 -0.368 123.803 -0.398
202302 -0.378 126.321 -0.400
202305 -0.351 128.034 -0.367
202308 -0.446 129.560 -0.460
202311 -0.354 130.958 -0.362
202402 -0.410 132.046 -0.415
202405 -0.385 132.818 -0.388
202408 -0.297 132.052 -0.301
202411 -0.434 133.000 -0.436
202502 -0.470 133.744 -0.470

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diamyd Medical AB  (OSTO:DMYD B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Diamyd Medical AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines